Tissue advanced glycation end products (AGEs), measured by skin autofluorescence, predict mortality in peritoneal dialysis

International Urology and Nephrology

Volumn 47, Issue 3, 2015, Pages 563-569

  Siriopol, Dimitrie ^a   Hogas, Simona ^a   Veisa, Gabriel ^a   Mititiuc, Irina ^a   Volovat, Carmen ^a   Apetrii, Mugurel ^a   Onofriescu, Mihai ^a   Busila, Irina ^a   Oleniuc, Mihaela ^a   Covic, Adrian ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

ESRD; Mortality; Sepsis; Tissue advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT;

ADULT; AGED; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHEMISTRY; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIABETIC NEPHROPATHY; FEMALE; FLUORESCENCE IMAGING; HUMAN; KIDNEY FAILURE, CHRONIC; MALE; METABOLISM; MIDDLE AGED; MORTALITY; RENAL REPLACEMENT THERAPY; SEPSIS; SKIN;

ADULT; AGED; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETIC NEPHROPATHIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OPTICAL IMAGING; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RENAL DIALYSIS; SEPSIS; SKIN;

EID: 84925537155     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-014-0870-3     Document Type: Article

References (45)

1. Baynes JW (2000) From life to death—the struggle between chemistry and biology during aging: the Maillard reaction as an amplifier of genomic damage. Biogerontology 1(3):235–246
2. Makita Z, Radoff S, Rayfield EJ et al (1991) Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325(12):836–842
3. Vishwanath V, Frank KE, Elmets CA, Dauchot PJ, Monnier VM (1986) Glycation of skin collagen in type I diabetes mellitus. Correlation with long-term complications. Diabetes 35:916–921
4. Beisswenger PJ, Makita Z, Curphey TJ et al (1995) Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 44(7):824–829
5. Miyata T, Wada Y, Cai Z et al (1997) Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 51(4):1170–1181
6. Aronson D (2003) Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 21(1):3–12
7. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C (2003) Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 18(7):1272–1280
8. Liliensiek B, Weigand MA, Bierhaus A et al (2004) Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 113(11):1641–1650
9. Lutterloh EC, Opal SM, Pittman DD et al (2007) Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 11(6):R122
10. Christaki E, Opal SM, Keith JC Jr et al (2011) A monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumonia. Shock 35(5):492–498
11. Meerwaldt R, Graaff R, Oomen PH et al (2004) Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 47(7):1324–1330
12. Meerwaldt R, Hartog JW, Graaff R et al (2005) Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 16(12):3687–3693
13. Gerrits EG, Lutgers HL, Smeets GH et al (2012) Skin autofluorescence: a pronounced marker of mortality in hemodialysis patients. Nephron Extra 2(1):184–191
14. Arsov S, Trajceska L, van Oeveren W et al (2013) Increase in skin autofluorescence and release of heart-type fatty acid binding protein in plasma predicts mortality of hemodialysis patients. Artif Organs 37(7):E114–E122
15. Kimura H, Tanaka K, Kanno M, et al (2014) Skin autofluorescence predicts cardiovascular mortality in patients on chronic hemodialysis. Ther Apher Dial Jan 24 (Epub ahead of print)
16. Mancia G, De Backer G et al (2007) 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25(6):1105–1187
17. American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1):S62
18. Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39(2):165–228
19. Meerwaldt R, Links T, Graaff R et al (2005) Simple noninvasive measurement of skin autofluorescence. Ann N Y Acad Sci 1043:290–298
20. Oleniuc M, Schiller A, Secara I et al (2012) Evaluation of advanced glycation end products accumulation, using skin autofluorescence, in CKD and dialysis patients. Int Urol Nephrol 44(5):1441–1449
21. McIntyre NJ, Chesterton LJ, John SG et al (2010) Tissue-advanced glycation end product concentration in dialysis patients. Clin J Am Soc Nephrol 5:51–55
22. Ueno H, Koyama H, Tanaka S et al (2008) Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metabolism 57(10):1452–1457
23. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW (1999) Alterations in nonenzymatic biochemistry in uremia: origin and significance of “carbonyl stress” in long-term uremic complications. Kidney Int 55:389–399
24. Meerwaldt R, Lutgers HL, Links TP et al (2007) Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 30(1):107–112
25. Lutgers HL, Gerrits EG, Graaff R et al (2009) Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 52(5):789–797
26. de Vos LC, Mulder DJ, Smit AJ et al (2014) Skin autofluorescence is associated with 5-year mortality and cardiovascular events in patients with peripheral artery disease. Arterioscler Thromb Vasc Biol 34(4):933–938
27. Kramer A, Stel VS, Caskey FJ et al (2012) Exploring the association between macroeconomic indicators and dialysis mortality. Clin J Am Soc Nephrol 7(10):1655–1663
28. Schmidt AM, Vianna M, Gerlach M et al (1992) Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267(21):14987–14997
29. Neeper M, Schmidt AM, Brett J et al (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267(21):14998–15004
30. Bopp C, Bierhaus A, Hofer S et al (2008) Bench-to-bedside review: the inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care 12(1):201
31. Hou FF, Ren H, Owen WF Jr et al (2004) Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 15:1889–1896
32. Koyama H, Nishizawa Y (2010) AGEs/RAGE in CKD: irreversible metabolic memory road toward CVD? Eur J Clin Invest 40(7):623–635
33. Yamagishi S, Nakamura K, Matsui T, Ueda S, Noda Y, Imaizumi T (2008) Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease. Cardiovasc Ther 26:50–58
34. Yamagishi S, Matsui T, Nakamura K, Noda Y, Imaizumi T (2008) Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr Pharm Des 14:487–495
35. Seong SY, Matzinger P (2004) Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 4(6):469–478
36. Schmidt AM, Yan SD, Yan SF, Stern DM (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108(7):949–955
37. Hori O, Brett J, Slattery T et al (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270(43):25752–25761
38. Hofmann MA, Drury S, Fu C et al (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97(7):889–901
39. Schmidt AM, Yan SD, Yan SF, Stern DM (2000) The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 1498(2–3):99–111
40. Yan SD, Zhu H, Zhu A et al (2000) Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 6(6):643–651
41. Bierhaus A, Schiekofer S, Schwaninger M et al (2001) Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50(12):2792–2808
42. Sousa MM, Yan SD, Stern D, Saraiva MJ (2000) Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Lab Invest 80(7):1101–1110
43. Degryse B, Bonaldi T, Scaffidi P et al (2001) The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 152(6):1197–1206
44. Schwenger V, Morath C, Salava A et al (2006) Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 17(1):199–207
45. De Vriese AS, Flyvbjerg A, Mortier S, Tilton RG, Lameire NH (2003) Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephrol 14(8):2109–2118